An Immunohistochemical Study of Adenomatoid Tumors of the Uterus and Fallopian Tube
Department of Pathology, Shizuoka City Shimizu Hospital, Shizuoka, Japan.Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry (Impact Factor: 2.01). 03/2012; 20(2):173-6. DOI: 10.1097/PAI.0b013e318229ea89
Immunohistochemical studies of adenomatoid tumor (AT) are rare in the English literature. The author reports herein immunoprofile of AT of the female genital organs. The materials are 4 cases of AT of the uterus and 1 case of AT of the fallopian tube. The ages of the patients were 37, 41, 43, 45, and 56 years. The sizes of ATs were 0.8 cm, 1 cm, 1.5 cm, 2 cm, and 4 cm. The 4 ATs of the uterus were composed of tubules and smooth muscles, whereas 1 AT of the fallopian tube was composed only of tubules. Immunohistochemically, the ATs were consistently positive for pancytokeratin AE1/3+++, pancytokeratin CAM5.2 ++, cytokeratin (CK) 7 +++, CK8 +, CK18++, CK19++, calretinin +++, and D2-40 ++. Estrogen receptor (ER) and progesterone receptor (PgR) was positive in 4 of 5 cases. CK34βE12 was positive in 1 of 5 case. The Ki-67 labeling ranged from 0.2% to 3%. The smooth muscles in uterine ATs were positive for α-smooth muscle actin, ER, and PgR. The ATs were consistently negative for CK5/6, CK14, CK20, EMA, HMB45, vimentin, desmin, CD31, CD34, factor VIII-relatedantigen, S100 protein, p53, CD68, CDK4, MDM2, and Ber-EP4. These data indicate that ATs consistently express pancytokeratin AE1/3, pancytokeratin CAM5.2, CK7, CK8, CK18, CK19, calretinin, and D2-40, that some ATs express CK34βE12, ER, and PgR, that ATs show little proliferative activity, and that ATs were consistently negative for CK5/6, CK14, CK20, EMA, HMB45, vimentin, desmin, CD31, CD34, factor VIII-related antigen, S100 protein, p53, CD68, CDK4, MDM2, and Ber-EP4.
- [Show abstract] [Hide abstract]
ABSTRACT: Podoplanin is a type I integral membrane glycoprotein that, because it is expressed in lymphatic endothelium, but not in vascular blood vessel endothelial cells, is commonly used in the identification of lymphatic endothelial differentiation in vascular endothelial neoplasms and lymphatic invasion by tumor. Because podoplanin is also expressed in mesothelial cells and fetal gonocytes, it has proved to be a useful marker for assisting in the differential diagnosis of mesotheliomas and germ cell tumors, particularly seminomas/dysgerminomas. Podoplanin expression has also been reported in a wide variety of other neoplasms, including hemangioblastomas, meningiomas, cartilaginous tumors, and follicular dendritic cell neoplasms. This article reviews the information that is currently available on the application of podoplanin immunostaining in diagnostic pathology.Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry 03/2013; 22(5). DOI:10.1097/PAI.0b013e31828a83c5 · 2.01 Impact Factor
- Zhonghua bing li xue za zhi Chinese journal of pathology 05/2013; 42(5):336-7. DOI:10.3760/cma.j.issn.0529-5807.2013.05.010
- [Show abstract] [Hide abstract]
ABSTRACT: Uncommon tumors in the uterus present diagnostic challenges. In some cases, the tumor subtype is usually seen outside of the gynecologic tract and the possibility of a uterine primary is not considered. In other cases, histologic overlap with more common uterine tumors leads to potential misdiagnosis. Finally, metastatic carcinoma may the uterus and cervix. Rarely, symptoms related to the uterine metastasis may precede diagnosis of an extra uterine primary. Without the proper clinical context, the possibility of a missed diagnosis is increased. One must first be aware of these possibilities, but immunoperoxidase studies are often necessary to confirm the diagnosis. In this review, unusual and metastatic tumors involving the uterine corpus and cervix and immunoperoxidase studies used to diagnosis such tumors are discussed.Seminars in Diagnostic Pathology 05/2014; 31(3). DOI:10.1053/j.semdp.2014.03.006 · 2.56 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.